Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Sort descending Recommendation Type Project Status Date Submission Received Date Recommendation Issued
TBC sotatercept Pulmonary arterial hypertension (WHO group 1) Pending
Adempas Riociguat Pulmonary arterial hypertension (WHO group 1) List with clinical criteria and/or conditions Complete
Darzalex Daratumumab Rd for MM Reimburse with clinical criteria and/or conditions Complete
N/A bevacizumab and lomustine Recurrent glioblastoma multiform Reimburse with clinical criteria and/or conditions Complete
Keytruda pembrolizumab recurrent, or metastatic cervical cancer Reimburse with clinical criteria and/or conditions Complete
Epkinly epcoritamab Relapsed or refractory diffuse large B-cell lymphoma Active
Columvi glofitamab Relapsed or refractory diffuse large B-cell lymphoma Reimburse with clinical criteria and/or conditions Active
Yescarta axicabtagene ciloleucel Relapsed or refractory follicular lymphoma Reimburse with clinical criteria and/or conditions Complete
Kymriah tisagenlecleucel Relapsed or refractory follicular lymphoma Reimburse with clinical criteria and/or conditions Complete
Breyanzi lisocabtagene maraleucel Relapsed or refractory large B-cell lymphoma Reimburse with clinical criteria and/or conditions Complete